FSRH CEU New Product Review: Kyleena® 19.5mg levonorgestrel-releasing intrauterine system

Posted 29 January 2018

Date: 29 Jan 2018

Type: FSRH News and Information

Kyleena® (Bayer plc) is a levonorgestrel (LNG) intrauterine system (IUS) newly launched in the UK that is licensed for contraceptive use for 5 years. The CEU has produced a new product review for Kyleena which summarises the key differences in the product and clinical characteristics between Kyleena and other LNG-IUS available in the UK.

Kyleena provides an additional highly effective option for long-acting reversible contraception. Systemic release of LNG is lower than with the 52mg LNG-IUS. The contraceptive effectiveness, side effect and adverse event profile of Kyleena is similar to that of other LNG-IUS devices. Kyleena is the most cost effective LNG-IUS per year of use if used for 5 years and may represent a small cost saving to service providers.

This new product review is intended to inform health professionals and is not a guidance document. For further information about medical eligibility, health benefits, side effects and health risks associated with use of LNG-IUS, please refer to FSRH guidance on intrauterine contraception at the link below. 

The new product review for Kyleena can be found at the link below.